Assay Detail
Functional
CHEMBL1666129
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiviral activity against HIV1 NL4-3 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA
6
Total Activities
6
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Human immunodeficiency virus 1 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Target
Human immunodeficiency virus 1 (CHEMBL378) ↗| Type | ORGANISM |
| Organism | Human immunodeficiency virus 1 |
Publication
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| EC50 | 6 | 7.96 | 8.96 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL2062277 | — | — | 1 | 8.96 |
| CHEMBL114 | SAQUINAVIR | 4.0 | 1 | 8.05 |
| CHEMBL129 | ZIDOVUDINE | 4.0 | 1 | 7.96 |
| CHEMBL518924 | MAVORIXAFOR | 4.0 | 1 | 7.46 |
| CHEMBL18442 | PLERIXAFOR | 4.0 | 1 | 7.39 |
| CHEMBL82301 | VICRIVIROC | 3.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL2062277 | — | EC50 | = | 1.1 | nM | 8.96 |
| CHEMBL114 | SAQUINAVIR | EC50 | = | 9.0 | nM | 8.05 |
| CHEMBL129 | ZIDOVUDINE | EC50 | = | 11.0 | nM | 7.96 |
| CHEMBL518924 | MAVORIXAFOR | EC50 | = | 35.0 | nM | 7.46 |
| CHEMBL18442 | PLERIXAFOR | EC50 | = | 41.0 | nM | 7.39 |
| CHEMBL82301 | VICRIVIROC | EC50 | > | 1000.0 | nM | - |